Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 4Carcinoma, Hepatocellular 4Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Colonic Neoplasms 2Breast Neoplasms 2Stage IA Pancreatic Adenocarcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Immunotherapy 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Esophageal Neoplasms 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Biliary Tract Neoplasms 1Advanced Pancreatic Cancer 1Advanced Biliary Tract Carcinoma 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

apatinib 3sintilimab 2Taxes 2Paclitaxel 2Oxaliplatin 2Hyperthermic Intraperitoneal Chemotherapy 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1XELOX 1Tegafur 1Tadalafil 1SHR-1701 1S 1 (combination) 1Platinum 1Magnetic Resonance Spectroscopy 1Injections 1Gastrectomy 1Drug Therapy 1Drug Evaluation 1Docetaxel 1Cytoreduction Surgical Procedures 1Cisplatin 1Capecitabine 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastric Adenocarcinoma × Tegafur × Clear all
NCT06196697 2024-06-27

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Harbin Medical University

Phase 2 Recruiting
50 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡